

Supplemental tables

S1: Best Response in Expansion Cohorts

| All treated patients | Fractionated Dosing | NPM1-mutated | Treatment Naïve* | Post-alloHSCT |
|--------------------------------------|----------------------------|---------------------|-------------------------|----------------------|
| | N=12 (%) | N=13 (%) | N=27 (%) | N=12 (%) |
| CR | 1 (8) | 1 (8) | 6 (22) | - |
| CRi | 2 (17) | - | 9 (33) | 1 (8) |
| mLFS | 2 (17) | 9 (69) | 4 (15) | 1 (8) |
| Resistant Disease | 6 (50) | 2 (15) | 7 (26) | 8 (67) |
| CRc Rate (CR+CRi) | 3 (25) | 1 (8) | 15 (56) | 1 (8) |
| Blast Clearance (CR+CRi+mLFS) | 5 (42) | 10 (77) | 19 (70) | 2 (17) |

*Includes Treatment Naïve cohort and 3 patients in the 40 mcg/kg dose escalation cohort who were treatment naive